NTHI · NeOnc Technologies Holdings, Inc.
AI read · Good for NTHI
The AI's read
A higher response rate gives NeOnc a stronger early sign that NEO100 may help patients with brain cancer. Still, this is a small Phase 2a group, and the FDA meeting is only to discuss a possible approval path and a proposed later trial. The drug remains under study, so the result is promising but not proof it works.